Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as when compared with imatinib, for the primary-line procedure of CML-CP. 5 hundred and nineteen patients with recently diagnosed CML-CP ended up randomly assigned to obtain dasatinib at a dose of one hundred mg after each day (259 people) https://joanh296wbf0.bligblogging.com/profile